Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.

Trial Details

NCT ID
NCT07167329
Phase
PHASE2
Sponsor
José Claudio Casali da Rocha
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Belzutifan
Locations (sample)
  • São Paulo, São Paulo, Brazil|-23.5475,-46.63611

Key Eligibility Criteria

  • Age ≥ 14 years.
  • Clinical or genetic confirmation of von Hippel-Lindau (VHL) syndrome.
  • Presence of measurable or progressive VHL-associated tumors, as defined by RECIST 1.1 or disease-specific imaging criteria.
  • ECOG performance status of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →